Skip to main content

Advertisement

Fig. 5 | EJNMMI Research

Fig. 5

From: Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies

Fig. 5

Graphs showing for each treatment group a average H69 tumour volume, b percentage of animals with tumours <1800 mm3, and c average tumour radioactivity at 24 h after administration of 177Lu-TATE A. Average tumour volume as a percentage compared with day 0. Tumours >1800 were taken out of the follow-up, which influenced the average tumour volume shown in the curves. The control group was treated with placebo, 30 MBq 177Lu-TATE was i.v. administered at day 0 to mice in groups 1, 4 and 5, at day 14 for group 6 and both at day 0 and day 14 for group 2. TMZ was administered orally once daily for 14 days at a dose of 50 mg/kg from day 0 to mice in groups 3, 4 and 6, starting at day 14 for group 5. Eight to ten mice/group. c Average tumour radioactivity: orange bar: groups 1, 2 (first dose), 4, 5; red bar: group 6; green bar: group 2 (second dose). Numbers, respectively, 14, 6 and 6 mice/group

Back to article page